Five Prime Therapeutics
Financials
Estimates*
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 39.0m | 49.0m | 14.0m | 13.0m | 16.0m | 12.0m |
| % growth | - | - | 26 % | (71 %) | (7 %) | 23 % | (25 %) |
| EBITDA | - | (149m) | (141m) | (130m) | (73.0m) | - | - |
| % EBITDA margin | - | (382 %) | (288 %) | (929 %) | (562 %) | - | - |
| Profit | - | (150m) | (140m) | (137m) | (84.0m) | 113m | 88.0m |
| % profit margin | - | (385 %) | (286 %) | (979 %) | (646 %) | 706 % | 733 % |
| EV / revenue | - | 15.8x | 6.5x | 3.9x | 39.5x | - | - |
| EV / EBITDA | - | -4.1x | -2.3x | -0.4x | -7.0x | - | - |
| R&D budget | 66.0m | 102m | 102m | 91.3m | - | - | - |
| R&D % of revenue | - | 262 % | 209 % | 652 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $9.5m | Early VC | |
$45.0m | Late VC | ||
N/A | Late VC | ||
| N/A | $7.5m | Late VC | |
$10.0m | Growth Equity VC | ||
| N/A | $62.4m Valuation: $208m | IPO | |
$21.0m | Post IPO Equity | ||
* | N/A | $75.0m | Post IPO Equity |
* | N/A | $115m | Post IPO Equity |
$1.9b Valuation: $1.9b 146.2x EV/LTM Revenues -26.0x EV/LTM EBITDA | Acquisition | ||
| Total Funding | $72.0m | ||
Related Content
Recent News about Five Prime Therapeutics
EditFive Prime Therapeutics, accessible at fiveprime.com, is a biotechnology company dedicated to developing innovative protein-based therapies for cancer patients. The company specializes in immuno-oncology, a field that focuses on using the body's immune system to fight cancer. Their mission is to significantly improve the lives of patients with serious diseases through groundbreaking treatments.
Five Prime operates in the biopharmaceutical market, targeting healthcare providers, research institutions, and pharmaceutical companies. Their primary clients are patients suffering from severe diseases, particularly various forms of cancer. The company’s business model revolves around research and development (R&D) of novel protein therapeutics, which are then brought to market through clinical trials and partnerships with larger pharmaceutical firms.
The company’s revenue streams come from multiple sources. These include licensing agreements, where other companies pay for the rights to use Five Prime’s technologies, and milestone payments, which are received when certain development goals are achieved. Additionally, Five Prime earns revenue from collaborative research agreements and potential future sales of their therapeutic products.
Five Prime’s pipeline is robust and continually expanding, with several promising candidates in late-stage development. Notable projects include Bemarituzumab, FPA150, FPT155, and TIM-3, all of which are undergoing clinical trials. The company emphasizes scientific innovation and fosters a culture of entrepreneurship and teamwork, aiming to push the boundaries of what is possible in medical science.
In summary, Five Prime Therapeutics is a forward-thinking biotech firm focused on developing novel protein therapies to treat serious diseases, primarily cancer. They operate in the biopharmaceutical market, serving healthcare providers and patients, and generate revenue through licensing, milestone payments, and collaborative research.
Keywords: biotechnology, immuno-oncology, protein therapeutics, cancer treatment, clinical trials, R&D, licensing agreements, milestone payments, pharmaceutical partnerships, innovative therapies.